{"id":"https://openalex.org/W4324136252","doi":"https://doi.org/10.1200/jco.2023.41.6_suppl.666","title":"A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).","display_name":"A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).","publication_year":2023,"publication_date":"2023-02-20","ids":{"openalex":"https://openalex.org/W4324136252","doi":"https://doi.org/10.1200/jco.2023.41.6_suppl.666"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2023.41.6_suppl.666","doi":"https://doi.org/10.1200/jco.2023.41.6_suppl.666","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.6_suppl.666","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058692226","display_name":"Neil J. Shah","orcid":"https://orcid.org/0000-0001-5752-6212","observed_orcids":["https://orcid.org/0000-0001-5752-6212"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neil J. Shah","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008861348","display_name":"Matthew T. Campbell","orcid":"https://orcid.org/0000-0003-1915-4491","observed_orcids":["https://orcid.org/0000-0003-1915-4491"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew T Campbell","raw_affiliation_strings":["University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080789872","display_name":"Shifeng S. Mao","orcid":"https://orcid.org/0000-0001-9532-0303","observed_orcids":["https://orcid.org/0000-0001-9532-0303"]},"institutions":[{"id":"https://openalex.org/I1310421338","display_name":"Allegheny Health Network","ror":"https://ror.org/0101kry21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1310421338"]},{"id":"https://openalex.org/I2800275141","display_name":"Allegheny General Hospital","ror":"https://ror.org/02gy6qp39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1310421338","https://openalex.org/I2800275141"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shifeng S. Mao","raw_affiliation_strings":["Allegheny Health Network Cancer Institute - AGH, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Allegheny Health Network Cancer Institute - AGH, Pittsburgh, PA","institution_ids":["https://openalex.org/I1310421338","https://openalex.org/I2800275141"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031016267","display_name":"Moshe Chaim Ornstein","orcid":"https://orcid.org/0000-0003-0184-3467","observed_orcids":["https://orcid.org/0000-0003-0184-3467"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Moshe Chaim Ornstein","raw_affiliation_strings":["Cleveland Clinic, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046123003","display_name":"Naomi Balzer Haas","orcid":"https://orcid.org/0000-0001-8907-7968","observed_orcids":["https://orcid.org/0000-0001-8907-7968"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Naomi B. Haas","raw_affiliation_strings":["University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA","institution_ids":["https://openalex.org/I4390039297"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Xin Gao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xin Gao","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103085920","display_name":"Hans J. Hammers","orcid":"https://orcid.org/0000-0002-6224-4559","observed_orcids":["https://orcid.org/0000-0002-6224-4559"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hans J. Hammers","raw_affiliation_strings":["UT Southwestern Medical Center, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT Southwestern Medical Center, Dallas, TX","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064611763","display_name":"Holavanahalli Keshava-Prasad","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210163348","display_name":"Comprehensive Cancer Centers of Nevada","ror":"https://ror.org/05etxbz89","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210163348"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holavanahalli Keshava-Prasad","raw_affiliation_strings":["Comprehensive Cancer Centers of Nevada, Las Vegas, NV"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Centers of Nevada, Las Vegas, NV","institution_ids":["https://openalex.org/I4210163348"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028369565","display_name":"Hongxia Yan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hongxia Yan","raw_affiliation_strings":["Aravive, Inc., Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Aravive, Inc., Houston, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019736396","display_name":"Vanessa Esquibel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vanessa Esquibel","raw_affiliation_strings":["Aravive Inc, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Aravive Inc, Houston, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111301566","display_name":"Robert B. Geller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert B. Geller","raw_affiliation_strings":["Aravive, Inc., Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Aravive, Inc., Houston, TX","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113915736","display_name":"Katy Beckermann","orcid":"https://orcid.org/0000-0002-4616-6140","observed_orcids":["https://orcid.org/0000-0002-4616-6140"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katy Beckermann","raw_affiliation_strings":["Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":11,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"6_suppl","first_page":"666","last_page":"666"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cabozantinib","display_name":"cabozantinib","score":0.9860000014305115},{"id":"https://openalex.org/keywords/clear-cell-renal-cell-carcinoma","display_name":"clear cell renal cell carcinoma","score":0.9919999837875366},{"id":"https://openalex.org/keywords/metastatic-renal-cell-carcinoma","display_name":"metastatic renal cell carcinoma","score":0.9319999814033508},{"id":"https://openalex.org/keywords/decoy-receptor","display_name":"decoy receptor","score":0.6700000166893005},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5590000152587891},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.8889999985694885},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.40400001406669617},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.7400000095367432},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9950000047683716},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5929999947547913}],"concepts":[{"id":"https://openalex.org/C2781064419","wikidata":"https://www.wikidata.org/wiki/Q795057","display_name":"Cabozantinib","level":3,"score":0.9826799631118774},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8791264295578003},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.647975742816925},{"id":"https://openalex.org/C2781278892","wikidata":"https://www.wikidata.org/wiki/Q18556340","display_name":"Clear cell renal cell carcinoma","level":3,"score":0.6175130605697632},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5947678089141846},{"id":"https://openalex.org/C172811965","wikidata":"https://www.wikidata.org/wiki/Q21110911","display_name":"GAS6","level":4,"score":0.5714050531387329},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5559984445571899},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4751693606376648},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43515336513519287},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3901197910308838},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.27198493480682373},{"id":"https://openalex.org/C101544691","wikidata":"https://www.wikidata.org/wiki/Q420511","display_name":"Receptor tyrosine kinase","level":3,"score":0.19780966639518738},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.11399254202842712}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2023.41.6_suppl.666","doi":"https://doi.org/10.1200/jco.2023.41.6_suppl.666","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.6_suppl.666","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9907000064849854,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4411622997","https://openalex.org/W4286296999","https://openalex.org/W4286294940","https://openalex.org/W4379333202","https://openalex.org/W4387826031","https://openalex.org/W3211809371","https://openalex.org/W4312139215","https://openalex.org/W4282964527","https://openalex.org/W4379281883","https://openalex.org/W4409129191"],"abstract_inverted_index":{"666":[0],"Background:":[1],"Activation":[2],"of":[3,13,80,124,139,145,165,213,254,286,290,295,311],"the":[4,122,130,323,344,378],"GAS6/AXL":[5],"pathway":[6],"promotes":[7],"tumor":[8],"cell":[9,70,72],"proliferation;":[10],"high":[11,301],"levels":[12,356],"GAS6":[14,355],"and":[15,23,98,151,236,242,293,318,367,388],"AXL":[16,40,44],"have":[17,86,384],"been":[18],"associated":[19],"with":[20,48,59,67,149,167,309,334],"drug":[21],"resistance":[22],"decreased":[24],"survival.":[25],"Batiraxcept":[26,56,267,328],"is":[27,61,227,346,365],"an":[28,88],"ultra-high":[29],"affinity":[30],"decoy":[31],"protein":[32],"that":[33],"captures":[34],"GAS6,":[35],"preventing":[36],"it":[37],"from":[38,94,102],"activating":[39],"signaling.":[41],"Serum":[42],"soluble":[43],"(sAXL)/GAS6":[45],"ratio":[46],"correlates":[47],"response":[49,90],"to":[50,120,209,271,315,349,376],"batiraxcept":[51,125,166],"in":[52,57,64,75,82,250,322,380],"advanced":[53],"ovarian":[54],"cancer.":[55],"combination":[58,345],"cabozantinib":[60,81,127,168,351],"being":[62],"evaluated":[63],"patients":[65,382],"(pts)":[66],"metastatic":[68],"clear":[69],"renal":[71],"carcinoma":[73],"(ccRCC)":[74],"this":[76],"study.":[77],"Prior":[78],"studies":[79],"similar":[83],"pt":[84],"populations":[85],"shown":[87],"overall":[89],"rate":[91],"(ORR)":[92],"ranging":[93],"15":[95,172,228],"\u2013":[96],"32.5%":[97],"progression-free":[99],"survival":[100],"(PFS)":[101],"3.7-7.2":[103],"months":[104],"(mo).":[105],"Methods:":[106],"Key":[107],"eligibility":[108],"criteria":[109],"include":[110],"previously":[111],"treated":[112],"ccRCC":[113,381],"pts,":[114],"excluding":[115],"prior":[116,196,211],"cabozantinib.":[117,335],"Objectives":[118],"were":[119,240,257,340,357],"determine":[121],"safety":[123,338],"plus":[126],"60":[128,182],"mg,":[129],"recommended":[131],"phase":[132],"2":[133,210,261],"dose":[134,164,247],"(RP2D),":[135],"ORR,":[136],"PFS,":[137],"duration":[138],"response.":[140,361],"Correlative":[141],"endpoints":[142],"included":[143],"assessment":[144],"baseline":[146,302],"serum":[147],"sAXL/GAS6":[148,303,325],"ORR":[150,285,305,317],"PFS.":[152],"Results:":[153],"In":[154],"Phase":[155],"1b":[156],"(P1b),":[157],"26":[158],"pts":[159,170,175,194,299],"received":[160,195,203,207],"at":[161],"least":[162],"one":[163],"(16":[169],"-":[171,176],"mg/kg;":[173],"10":[174],"20":[177],"mg/kg).":[178],"Median":[179,217],"age":[180],"was":[181,220,268,306,329],"(range":[183,215,223],"40-81),":[184],"male":[185],"85%":[186,205],"(n=22),":[187],"IMDC":[188],"intermediate/poor":[189],"risk":[190],"77%":[191],"(n=20).":[192],"All":[193],"immuno-oncology":[197],"(IO)":[198],"therapy,":[199],"54%":[200,251],"(n=14)":[201],"also":[202],"VEGF-TKI;":[204],"(n=22)":[206],"1":[208,259],"lines":[212],"therapy":[214],"1-6).":[216],"follow-up":[218],"time":[219],"11.6":[221],"mo":[222,321],"3.7-18).":[224],"The":[225,280,362],"RP2D":[226],"mg/kg.":[229],"Related":[230],"adverse":[231],"events":[232],"(AE)":[233],"any":[234],"grade":[235,237,258],"\u2265":[238],"3":[239],"100%":[241],"39%":[243],"(n=10),":[244],"respectively.":[245],"Cabozantinib":[246],"reductions":[248],"occurred":[249],"(n=14).":[252],"AEs":[253],"special":[255],"interest":[256],"or":[260,276],"infusion":[262],"related":[263],"reactions,":[264],"27%":[265],"(n=7).":[266],"discontinued":[269],"due":[270],"disease":[272],"progression":[273],"62%":[274],"(n=16)":[275],"toxicity":[277],"12%":[278],"(n=3).":[279],"table":[281],"shows":[282],"P1b":[283],"efficacy,":[284],"42%,":[287],"median":[288],"PFS":[289],"9.3":[291,312],"mo,":[292,313],"DCR":[294],"84%.":[296],"Twenty":[297],"(77%)":[298],"had":[300],"levels;":[304],"55%":[307],"(11/20)":[308],"mPFS":[310,319],"compared":[314,348],"0%":[316],"6.4":[320],"low":[324],"pts.":[326],"Conclusions:":[327],"well":[330],"tolerated":[331],"when":[332],"combined":[333],"No":[336],"new":[337],"signals":[339],"noted.":[341],"Efficacy":[342],"for":[343,359],"encouraging":[347],"historical":[350],"monotherapy":[352],"data.":[353],"Higher":[354],"predictive":[358],"treatment":[360],"P2":[363],"accrual":[364],"complete":[366],"efficacy":[368,379],"data":[369],"are":[370],"maturing.":[371],"A":[372],"P3":[373],"trial":[374,392],"plans":[375],"evaluate":[377],"who":[383],"progressed":[385],"on":[386],"IO-based":[387],"VEGF-TKI":[389],"therapies.":[390],"Clinical":[391],"information:":[393],"NCT04300140":[394],".":[395],"[Table:":[396],"see":[397],"text]":[398]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-03-15T00:00:00"}